image
Healthcare - Drug Manufacturers - General - NASDAQ - GB
$ 66.6
-0.463 %
$ 207 B
Market Cap
32.17
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AZN stock under the worst case scenario is HIDDEN Compared to the current market price of 66.6 USD, AstraZeneca PLC is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AZN stock under the base case scenario is HIDDEN Compared to the current market price of 66.6 USD, AstraZeneca PLC is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AZN stock under the best case scenario is HIDDEN Compared to the current market price of 66.6 USD, AstraZeneca PLC is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
45.8 B REVENUE
3.29%
8.19 B OPERATING INCOME
118.07%
6.9 B NET INCOME
175.85%
10.3 B OPERATING CASH FLOW
5.48%
-4.06 B INVESTING CASH FLOW
-37.30%
-6.57 B FINANCING CASH FLOW
3.75%
13.6 B REVENUE
4.85%
2.11 B OPERATING INCOME
-23.31%
1.83 B NET INCOME
-5.14%
3.38 B OPERATING CASH FLOW
9.66%
-1.51 B INVESTING CASH FLOW
47.28%
-4.13 B FINANCING CASH FLOW
-238.05%
Balance Sheet AstraZeneca PLC
image
Current Assets 25.1 B
Cash & Short-Term Investments 5.86 B
Receivables 8.41 B
Other Current Assets 10.8 B
Non-Current Assets 76.1 B
Long-Term Investments 1.78 B
PP&E 10.5 B
Other Non-Current Assets 63.8 B
Current Liabilities 30.5 B
Accounts Payable 3.27 B
Short-Term Debt 5.4 B
Other Current Liabilities 21.9 B
Non-Current Liabilities 31.4 B
Long-Term Debt 23.2 B
Other Non-Current Liabilities 8.19 B
EFFICIENCY
Earnings Waterfall AstraZeneca PLC
image
Revenue 45.8 B
Cost Of Revenue 8.04 B
Gross Profit 37.8 B
Operating Expenses 29.6 B
Operating Income 8.19 B
Other Expenses 1.29 B
Net Income 6.9 B
RATIOS
82.45% GROSS MARGIN
82.45%
17.88% OPERATING MARGIN
17.88%
13.00% NET MARGIN
13.00%
15.21% ROE
15.21%
5.89% ROA
5.89%
10.62% ROIC
10.62%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AstraZeneca PLC
image
Net Income 6.9 B
Depreciation & Amortization 4.93 B
Capital Expenditures -3.78 B
Stock-Based Compensation 579 M
Change in Working Capital 300 M
Others -1.4 B
Free Cash Flow 6.57 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AstraZeneca PLC
image
Wall Street analysts predict an average 1-year price target for AZN of $86 , with forecasts ranging from a low of $82 to a high of $89 .
AZN Lowest Price Target Wall Street Target
82 USD 23.12%
AZN Average Price Target Wall Street Target
86 USD 29.13%
AZN Highest Price Target Wall Street Target
89 USD 33.63%
4. DIVIDEND ANALYSIS
0.65% DIVIDEND YIELD
0.49 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership AstraZeneca PLC
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Deadline Approaching: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming February 21, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ASTRAZENECA PLC (AZN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE. businesswire.com - 1 week ago
J&J lung cancer treatment extends lives versus AstraZeneca drug Johnson & Johnson (NYSE:JNJ) has said its chemotherapy-free combination extended lung cancer patients' lives compared to AstraZeneca PLC (LSE:AZN)'s Tagrisso drug in a head-to-head study. The combination showed “clinically meaningful and statistically significant improvement in overall survival” against Astra's blockbuster treatment, a Tuesday statement said. proactiveinvestors.com - 1 week ago
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit – AZN NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). globenewswire.com - 1 week ago
Investors Are Invited To Join The Schall Law Firm In A Securities Fraud Case Against AstraZeneca PLC LOS ANGELES, CA / ACCESSWIRE / January 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025. accesswire.com - 1 week ago
J&J says its lung cancer drug combination keeps people alive longer Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial. J&J is trying to supplant AstraZeneca's blockbuster Tagrisso, a once-daily pill that has transformed the treatment of non-small cell lung cancer with EGFR mutations. cnbc.com - 1 week ago
AstraZeneca pipeline undervalued and underrated, broker suggests AstraZeneca PLC (LSE:AZN) decline has gone too far, according to the analysts at Berenberg, who note that attention in 2025 switches to the breast cancer, hypertension and obesity pipelines. Currently, the broker says that the shares are trading in line with the value of marketed drugs only, with no value assigned to the pipeline. proactiveinvestors.co.uk - 1 week ago
J&J's combo extends patients' lives in head-to-head study with AstraZeneca's drug Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending lives of patients with a type of lung cancer, compared to AstraZeneca's blockbuster drug Tagrisso. reuters.com - 1 week ago
Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=121173&wire=1 or contact Joseph E. Levi, Esq. accesswire.com - 1 week ago
AZN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Stockholders Have Opportunity to Lead Class Action Lawsuit! NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"). accesswire.com - 1 week ago
AZN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Astrazeneca business and prospects, resulting in its stock trading at inflated prices. businesswire.com - 1 week ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca Lawsuit - AZN NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. prnewswire.com - 1 week ago
Levi & Korsinsky Notifies Shareholders of AstraZeneca PLC(AZN) of a Class Action Lawsuit and an Upcoming Deadline NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=121107&wire=1 or contact Joseph E. Levi, Esq. accesswire.com - 1 week ago
8. Profile Summary

AstraZeneca PLC AZN

image
COUNTRY GB
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 207 B
Dividend Yield 0.65%
Description AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Contact 1 Francis Crick Avenue, Cambridge, CB2 0AA https://www.astrazeneca.com
IPO Date May 12, 1993
Employees 89900
Officers Ms. Pam P. Cheng EVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board Dr. Aradhana Sarin M.D. Chief Financial Officer & Executive Director Dr. Susan Mary Galbraith M.D., Ph.D. Executive Vice President of Oncology Research & Development Ms. Iskra Reic Executive Vice President of International Mr. Jeffrey Pott J.D. CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board Mr. David Fredrickson Executive Vice-President of Oncology Business Unit Dr. Ruud Dobber Ph.D. Executive Vice-President of BioPharmaceuticals Business Unit Mr. Andrew P. Barnett Head of Investor Relations Gonzalo Vina Head of Global Media Relations Mr. Pascal Soriot D.V.M., M.B.A. Chief Executive Officer & Executive Director